about
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenDiscovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapyNational Athletic Trainers' Association position statement: management of asthma in athletes.The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.Biomarkers in asthma: a real hope to better manage asthma.Montelukast: data from clinical trials in the management of asthma.Structural basis for lipoxygenase specificity. Conversion of the human leukocyte 5-lipoxygenase to a 15-lipoxygenating enzyme species by site-directed mutagenesis.Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapiesRationales for treating IgA nephropathies.Montelukast: a review of its therapeutic potential in persistent asthma.Anti-leukotrienes in asthma: yet to arrive.Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma.Arachidonic acid metabolism in inflammatory cells of patients with bronchial asthma.Targeting cysteinyl leukotrienes in patients with rhinitis, sinusitis and paranasal polyps.Guidance on the diagnosis and management of asthma among adults in resource limited settings.Better breathing or better living? A qualitative analysis of the impact of asthma medication acquisition on standard of living and quality of life in low-income families of children with asthma.Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study.Biologically active sesquiterpene coumarins from Ferula species.Montelukast: its role in the treatment of childhood asthma.New directions in asthma drug therapy.Anti-leukotrienes in Childhood Asthma.Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity.The answer is Buerger's disease, and the question is...Comparative effect of triamcinolone, nedocromil and montelukast on asthma control in children: A randomized pragmatic study.Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin.Acute toxicity of marking pen emissions.Exercise for asthma patients: little risk, big rewardsLeukotrienes as Mediators of Airway ObstructionShould Antileukotriene Therapies Be Used Instead of Inhaled Corticosteroids in Asthma?
P2860
Q24197682-5C0BFD21-B49C-47E4-8B37-79B37EA678F1Q24247433-8F9FD20A-80D2-4309-8AF0-6D67F4333897Q28534270-D9007F62-5DE3-47EC-A889-F3086484FE86Q28769235-CEA855B4-056B-4D98-86B9-7EB8D9B6F164Q30234961-FE8C2A2C-60BB-46A7-B085-658847319AB7Q30417360-AC21F00C-0D59-4DB1-AE02-69640A9E93B7Q31448541-B377830B-0E4E-406A-A0B8-CDFEC05A184EQ31454807-AEA921DC-A9F6-457E-88E6-8707D17BE1C0Q33662463-8A6A4A8F-E872-4B9C-A96F-E255CE549F58Q33863555-CD669E0E-9ACC-4C64-A9EF-57550FCCD77EQ33914371-678733A8-9CBE-4AC3-8DE0-818DC981AEBAQ33930448-0A1CBDF4-F542-459A-B6DA-AAF0F5D5D066Q33978718-B245E602-7C9B-45EE-9058-0E3508B563F6Q33987180-963BE1DC-B10D-4551-8475-1F58784353DEQ35627765-0731932E-9C5B-4F12-A8FC-2D198B806E81Q36612656-ECC2C3A3-B73D-4AB4-8FDA-2967F356C1D1Q37083298-08A873E6-DFBD-4103-8DE0-B2EC9FA472CFQ37661026-F2894320-3FB5-4B40-8BD9-10762D1C9C18Q37804741-1C2FA4EB-CF32-4726-A9B6-03459851C2D1Q38288335-7A461AEE-DF86-41A9-A0BC-DB9239FB9589Q41713356-C3B104EC-156C-4C5A-89AB-F03DC60794FBQ42046917-7A4DE17A-4E70-47CD-A12A-18947E9F748CQ42756727-DC87A453-5596-460B-AE4B-1059A0CEB9ABQ43124660-781208DE-9322-4350-A9A1-D372961C836FQ45014739-34DCD933-2D7D-4F81-80F1-E5E8C4CD0E9BQ46616233-F82C2B27-2F81-40E4-8C6E-1339F3685BA1Q47260179-A3CCA93F-B4A0-4A17-B716-A564EA7D1FE6Q51673719-8C8A3737-CAD1-484D-9C17-6479A70322D3Q57133486-11AE985D-5EBD-4CEC-9975-B1AF7FEBD91CQ57240752-7B21B272-34DB-4118-A895-BE25DF2314F6Q57240765-FA4D3047-6C31-4489-9C48-6536E034D125
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Antileukotrienes in the treatment of asthma.
@ast
Antileukotrienes in the treatment of asthma.
@en
Antileukotrienes in the treatment of asthma.
@nl
type
label
Antileukotrienes in the treatment of asthma.
@ast
Antileukotrienes in the treatment of asthma.
@en
Antileukotrienes in the treatment of asthma.
@nl
prefLabel
Antileukotrienes in the treatment of asthma.
@ast
Antileukotrienes in the treatment of asthma.
@en
Antileukotrienes in the treatment of asthma.
@nl
P2093
P1476
Antileukotrienes in the treatment of asthma.
@en
P2093
P304
P356
10.7326/0003-4819-127-6-199709150-00009
P407
P577
1997-09-01T00:00:00Z